

## Datasheet: MCA401

**BATCH NUMBER 172098**

<b>Description:</b>	MOUSE ANTI INFLUENZA A MATRIX PROTEIN
<b>Specificity:</b>	INFLUENZA A MATRIX PROTEIN
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	GA2B
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry			▪	
Immunohistology - Frozen			▪	
Immunohistology - Paraffin	▪			
ELISA			▪	
Immunoprecipitation			▪	
Western Blotting	▪			
Immunofluorescence	▪			1/100

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Viral
<b>Product Form</b>	Purified IgG - liquid
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant.
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	<0.1% Sodium Azide (NaN <sub>3</sub> )

<b>Approx. Protein Concentrations</b>	IgG concentration 1.0 mg/ml
<b>Immunogen</b>	Influenza A / Puerto Rico / 8 / 34 (H1N1) and A/Bangkok / 1 / 79 (H3N2) viruses.
<b>External Database Links</b>	<p><b>UniProt:</b></p> <p><a href="#">P03485</a>      <a href="#">Related reagents</a></p> <p><a href="#">P03487</a>      <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b></p> <p><a href="#">956527</a>    M1    <a href="#">Related reagents</a></p>
<b>RRID</b>	AB_322157
<b>Fusion Partners</b>	Spleen cells from immunised BALB/c mice were fused with cells of the P3 Ag8.653 mouse myeloma cell line.
<b>Specificity</b>	<p><b>Mouse anti Influenza A matrix protein 1 antibody, clone GA2B</b> recognizes an epitope within the influenza A matrix protein 1. In both strains of virus used as immunogen to isolate clone GA2B, the matrix protein 1 is a 252 amino acid, highly conserved viral protein playing a crucial role in replication.</p> <p>Mouse anti Influenza A matrix protein 1 antibody, clone GA2B can be used in influenza A IFA typing in conjunction with <a href="#">Mouse anti Influenza A matrix protein, clone AA5H</a>.</p>
<b>Purity</b>	>90% IgG content as established by SDS PAGE
<b>References</b>	<ol style="list-style-type: none"> <li>Latham, T. &amp; Galarza, J.M. (2001) Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. <a href="#">J Virol. 75 (13): 6154-65.</a></li> <li>Viemann, D. <i>et al.</i> (2011) H5N1 virus activates signaling pathways in human endothelial cells resulting in a specific imbalanced inflammatory response. <a href="#">J Immunol. 186 (1): 164-73.</a></li> <li>Yamamoto, Y. <i>et al.</i> (2008) Avian influenza virus (H5N1) replication in feathers of domestic waterfowl. <a href="#">Emerg Infect Dis. 14: 149-51.</a></li> <li>Doucet, J.D. <i>et al.</i> (2011) Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes. <a href="#">J Gen Virol. 92 (Pt 5): 1162-71.</a></li> <li>Tanimura N <i>et al.</i> (2006) Pathology of fatal highly pathogenic H5N1 avian influenza virus infection in large-billed crows (<i>Corvus macrorhynchos</i>) during the 2004 outbreak in Japan. <a href="#">Vet Pathol. 43 (4): 500-9.</a></li> <li>Kirkeby, S. <i>et al.</i> (2009) Infection with human H1N1 influenza virus affects the expression of sialic acids of metaplastic mucous cells in the ferret airways. <a href="#">Virus Res. 144: 225-32.</a></li> <li>Pauli, E.K. <i>et al.</i> (2008) Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. <a href="#">PLoS Pathog. 4(11): e1000196.</a></li> <li>Eierhoff, T. <i>et al.</i> (2010) The epidermal growth factor receptor (EGFR) promotes uptake</li> </ol>

- of influenza A viruses (IAV) into host cells. [PLoS Pathog. 6. pii: e1001099.](#)
9. Wang, D. *et al.* (2010) The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza A virus to bud into virus-like particles. [J Virol. 84: 4673-81.](#)
10. Kang, S.M. *et al.* (2009) Induction of long-term protective immune responses by influenza H5N1 virus-like particles. [PLoS One. 4: e4667.](#)
11. Luig, C. *et al.* (2010) MAP kinase-activated protein kinases 2 and 3 are required for influenza A virus propagation and act via inhibition of PKR. [FASEB J. 24: 4068-77.](#)
12. Schmolke, M. *et al.* (2009) Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. [J Immunol. 183: 5180-9.](#)
13. Reinhardt, J. and Wolff, T. (2000) The influenza A virus M1 protein interacts with the cellular receptor of activated C kinase (RACK) 1 and can be phosphorylated by protein kinase C. [Vet Microbiol. 74: 87-100.](#)
14. Das, S.C. *et al.* (2012) The Highly Conserved Arginine Residues at Positions 76 through 78 of Influenza A Virus Matrix Protein M1 Play an Important Role in Viral Replication by Affecting the Intracellular Localization of M1. [J Virol. 86: 1522-30.](#)
15. Liu, Y.V. *et al.* (2011) Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. [Vaccine. 29: 6606-13.](#)
16. Moncorgé, O. *et al.* (2013) Investigation of influenza virus polymerase activity in pig cells. [J Virol. 87 \(1\): 384-94.](#)
17. Khapersky, D.A. *et al.* (2012) Influenza A virus inhibits cytoplasmic stress granule formation. [FASEB J. 26: 1629-39.](#)
18. Friesenhagen, J. *et al.* (2012) Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. [J Leukoc Biol. 92: 11-20.](#)
19. Londrigan, S.L. *et al.* (2015) Infection of Mouse Macrophages by Seasonal Influenza Viruses Can Be Restricted at the Level of Virus Entry and at a Late Stage in the Virus Life Cycle. [J Virol. 89 \(24\): 12319-29.](#)
20. Sadewasser, A. *et al.* (2017) Quantitative Proteomic Approach Identifies Vpr Binding Protein as Novel Host Factor Supporting Influenza A Virus Infections in Human Cells. [Mol Cell Proteomics. 16 \(5\): 728-42.](#)
21. Liu, Y.V. *et al.* (2015) Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. [Vaccine. 33 \(18\): 2152-8.](#)
22. Huang, M.T. *et al.* (2015) DcR3 suppresses influenza virus-induced macrophage activation and attenuates pulmonary inflammation and lethality. [J Mol Med \(Berl\). 93 \(10\): 1131-43.](#)
23. Al-Mubarak, F. *et al.* (2015) Identification of morphological differences between avian influenza A viruses grown in chicken and duck cells. [Virus Res. 199: 9-19.](#)
24. Yang, C.H. *et al.* (2017) Influenza A virus upregulates PRPF8 gene expression to increase virus production. [Arch Virol. 162 \(5\): 1223-35.](#)
25. Smith, G.E. *et al.* (2017) Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets. [Virology. 509: 90-97.](#)
26. Usui, T. *et al.* (2020) Outbreaks of highly pathogenic avian influenza in zoo birds caused by HA clade 2.3.4.4 H5N6 subtype viruses in Japan in winter 2016. [Transbound Emerg Dis. 67 \(2\): 686-697.](#)
27. Frensing, T. *et al.* (2016) Influenza virus intracellular replication dynamics, release

kinetics, and particle morphology during propagation in MDCK cells. [Appl Microbiol Biotechnol. 100 \(16\): 7181-92.](#)

28. Melano, I. *et al.* (2021) Effects of Basic Amino Acids and Their Derivatives on SARS-CoV-2 and Influenza-A Virus Infection. [Viruses. 13 \(7\):1301.](#)

29. Soda, K. *et al.* (2022) Susceptibility of herons (family: *Ardeidae*) to clade 2.3.2.1 H5N1 subtype high pathogenicity avian influenza virus. [Avian Pathol. 51 \(2\): 146-53.](#)

30. Soda, K. *et al.* (2022) Susceptibility of common family Anatidae bird species to clade 2.3.4.4e H5N6 high pathogenicity avian influenza virus: an experimental infection study. [BMC Vet Res. 18 \(1\): 127.](#)

31. Kwasnik, M. *et al.* (2023) Protein-Coding Region Derived Small RNA in Exosomes from Influenza A Virus-Infected Cells. [Int J Mol Sci. 24\(1\):867.](#)

32. Yang, M.L. *et al.* (2023) Upregulation of galectin-3 in influenza A virus infection promotes viral RNA synthesis through its association with viral PA protein. [J Biomed Sci. 30 \(1\): 14.](#)

33. Soda, K. *et al.* (2023) Susceptibility of common dabbling and diving duck species to clade 2.3.2.1 H5N1 high pathogenicity avian influenza virus: an experimental infection study. [J Vet Med Sci. 85 \(9\): 942-9.](#)

34. Kühnl, A. *et al.* (2018) Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus. [mBio. 9 \(4\): e01345-18.](#)

35. Uno, Y. *et al.* (2020) Pathogenicity of clade 2.3.2.1 H5N1 highly pathogenic avian influenza virus in American kestrel (*Falco sparverius*). [Avian Pathol. 49 \(5\): 515-525.](#)

---

**Storage**

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

**Guarantee**

12 months from date of despatch

---

**Health And Safety Information**

Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/MCA401>

---

**Regulatory**

For research purposes only

---

## Related Products

### Recommended Secondary Antibodies

Goat Anti Mouse IgG IgA IgM (STAR87...) [HRP](#)

Goat Anti Mouse IgG (STAR70...) [FITC](#)

Rabbit Anti Mouse IgG (STAR13...) [HRP](#)

Rabbit Anti Mouse IgG (STAR9...) [FITC](#)

Goat Anti Mouse IgG (STAR77...) [HRP](#)

Goat Anti Mouse IgG (STAR76...) [RPE](#)

Goat Anti Mouse IgG (Fc) (STAR120...) [FITC](#), [HRP](#)

Goat Anti Mouse IgG (H/L) (STAR117...) [Alk. Phos.](#), [DyLight®488](#), [DyLight®550](#),  
[DyLight®650](#), [DyLight®680](#), [DyLight®800](#),  
[FITC](#), [HRP](#)  
Rabbit Anti Mouse IgG (STAR12...) [RPE](#)

**Product inquiries:** [www.bio-rad-antibodies.com/technical-support](http://www.bio-rad-antibodies.com/technical-support)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](http://bio-rad-antibodies.com/datasheets)  
'M418836:230427'

**Printed on 18 Sep 2025**

---

© 2025 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)